// App-Quantinova.ai

P300 : Individualized Onabotulinumtoxina Treatment for Spasticity in Multiple Sclerosis Resulted in High Patient and Clinician Satisfaction: The Aspire Study

Researchers

Presenter

  • Daniel S Bandari

Principal Investigators

  • Angeli Mayadev

  • Mohamed Sakel

  • Alberto Esquenazi

  • Joan Largent

  • Aleksej Zuzek

Medical Centers

  • Multiple Sclerosis Center of California & Research Group at the Hoag Neurosciences Institute, Newport Beach, CA

  • Multiple Sclerosis Center Rehabilitation Program – Swedish Neuroscience Institute, Seattle, WA

  • East Kent Hospitals University NHS Foundation Trust, Kent & Canterbury Hospital, Canterbury, United Kingdom

  • MossRehab Gait and Motion Analysis Lab, Elkins Park, PA

  • IQVIA Real-World Evidence Solutions, Cambridge, MA

  • Allergan plc, Irvine, CA and Gerard E Francisco, University of Texas McGovern Medical School and TIRR Memorial Hermann, Houston, TX

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Multiple Sclerosis

Biomarkers

  • N/A

Drug/Treatment

  • OnabotulinumtoxinA

Outcome

  • N/A

Study Design

  • Observational

  • Multinational

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • NCT01930786

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved